Browse Studies — Arctuva

Phase 1

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) gene transfer treatment for X-linked severe combined immunodeficien…

X-linked Severe Combined Immunodeficiency (XSCID)

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT01306019

The Determination of Genetic Basis Of Immunodeficiency

This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID). Patients with immunodeficiencies may be …

Severe Combined Immunodeficiency

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT00055172

Phase 1

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected …

Severe Combined Immunodeficiency, X LinkedGene Therapy

Estimated

~$10 – $7,500

David WilliamsNCT03311503

Phase 1

Phase I/II Safety and Efficacy Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) in Newly Diagnosed Patients Using Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells

This study aims to determine if a new method can be used to treat Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a severe form of primary immun…

Severe Combined Immunodeficiency

Estimated

~$10 – $5,625

University of California, San FranciscoNCT03538899